Guardant Health Director Sells 100 Shares at $65.84 on 2025-09-02
PorAinvest
miércoles, 3 de septiembre de 2025, 6:56 pm ET1 min de lectura
GH--
Guardant Health, Inc. (GH) has announced that Director Joyce Meghan V. sold 100 shares of the company's common stock on September 2, 2025. The shares were sold at a price of $65.84 per share, resulting in an aggregate market value of $6,584.
The transaction was executed through Charles Schwab & Co., Inc. and is part of the company's equity compensation program. The shares were acquired by Director Joyce Meghan V. through restricted stock lapses: 34 shares on June 12, 2025, and 66 shares on July 4, 2025. These shares were listed as part of the company's compensation package [1].
This sale is part of a series of recent insider transactions. In June 2025, Director Joyce Meghan V. sold 100 shares for $4,166 on June 2, 2025, and 3,337 shares for $157,573 on June 13, 2025. The filings disclose these transactions, providing transparency to investors and regulatory bodies [1].
The recent positive performance of Guardant Health's stock, which has seen a 4.82% increase amid promising new growth plans and strategic partnerships, may have influenced the sale. The company has recently formed a partnership with the American Cancer Society to enhance cancer screenings and promote health equity [2]. Additionally, analysts have revised their price targets upward, reflecting the company's robust financial guidance and promising future outlook [2].
Despite the recent insider sales, the overall market sentiment for Guardant Health remains positive. The company's strategic partnerships and financial performance are seen as strong drivers of future growth.
References:
[1] https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-c59cd2c49d75.html
[2] https://stockstotrade.com/news/guardanthealthinc-gh-news-2025_08_30/
Guardant Health, Inc. (GH) announced that Director Joyce Meghan V. has recently sold 100 shares at a price of $65.84 per share on September 2, 2025.
Title: Guardant Health, Inc. Director Joyce Meghan V. Sells 100 Shares on September 2, 2025Guardant Health, Inc. (GH) has announced that Director Joyce Meghan V. sold 100 shares of the company's common stock on September 2, 2025. The shares were sold at a price of $65.84 per share, resulting in an aggregate market value of $6,584.
The transaction was executed through Charles Schwab & Co., Inc. and is part of the company's equity compensation program. The shares were acquired by Director Joyce Meghan V. through restricted stock lapses: 34 shares on June 12, 2025, and 66 shares on July 4, 2025. These shares were listed as part of the company's compensation package [1].
This sale is part of a series of recent insider transactions. In June 2025, Director Joyce Meghan V. sold 100 shares for $4,166 on June 2, 2025, and 3,337 shares for $157,573 on June 13, 2025. The filings disclose these transactions, providing transparency to investors and regulatory bodies [1].
The recent positive performance of Guardant Health's stock, which has seen a 4.82% increase amid promising new growth plans and strategic partnerships, may have influenced the sale. The company has recently formed a partnership with the American Cancer Society to enhance cancer screenings and promote health equity [2]. Additionally, analysts have revised their price targets upward, reflecting the company's robust financial guidance and promising future outlook [2].
Despite the recent insider sales, the overall market sentiment for Guardant Health remains positive. The company's strategic partnerships and financial performance are seen as strong drivers of future growth.
References:
[1] https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-c59cd2c49d75.html
[2] https://stockstotrade.com/news/guardanthealthinc-gh-news-2025_08_30/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios